Zydus Life said that the approval follows the successful completion of a Phase II proof-of-concept trial, jointly conducted by Zydus and ICMR, which met its primary endpoint and demonstrated positive efficacy and safety outcomes.
Zydus Life said that the approval follows the successful completion of a Phase II proof-of-concept trial, jointly conducted by Zydus and ICMR, which met its primary endpoint and demonstrated positive efficacy and safety outcomes.